Baird served as joint-bookrunner on this offering
AboutExact Sciences Corporation (“Exact Sciences” or the “Company”) (NASDAQ: EXAS) recently completed a follow-on offering of 9,775,000 shares of common stock at $15.50 per share, generating gross proceeds of approximately $151.5 million. The Company intends to use the net proceeds of this offering to fund expansion of Cologuard® commercialization activities, to fund product development efforts, and for general corporate and working capital purposes.
Exact Sciences is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer. The Company has exclusive intellectual property protecting its noninvasive, molecular screening technology for the detection of colorectal cancer. Cologuard is included in the American Cancer Society’s (2014) colorectal cancer screening guidelines and the recommendations of the United States Preventive Services Task Force (2016). Stool DNA is included in the combined screening guidelines of the American Cancer Society/United States Multi-Society Task Force/American College of Radiology (2008) and the American College of Gastroenterology guidelines (2009). Exact Sciences is based in Madison, Wisconsin.
For additional information about this transaction, please contact:
- July 2016
- Exact Sciences Corporation
- Target Location
- North America